The trial showed significant results for both progression-free and overall survival. Genmab plans to discuss next steps with regulators; its shares rose 9.48% at the Oct. 23 close.
Genmab showcased epcoritamab’s expanded potential across lymphomas and unveiled AI-driven R&D initiatives at major oncology conferences to support pipeline growth.
